2.1
Acoramidis (Beyonttra, Bayer) is indicated for the 'treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM)'.
2 Information about acoramidis
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for acoramidis.
Price
2.3
The list price of acoramidis is £8,547.60 for 120 x 356‑mg tablets (excluding VAT; company submission).
2.4
The company has a commercial arrangement. This makes acoramidis available to the NHS with a discount. The size of the discount is commercial in confidence.
Sustainability
2.5
For information, the Carbon Reduction Plan for UK carbon emissions is published on Bayer's webpage on sustainability.